Who it has to work for
Six perspectives that have to align.
Adoption depends on meaningful value transfer: how well our technology answers the critical needs and questions of each healthcare stakeholder.
P1 · Patient / Families
“What would make this easy enough that I would actually do it?”
Yes, it’s simple! It’s a gentle swab of the inside of your cheek. It takes 10 seconds to perform. No needles, no scans and no radiation. Your result goes to your doctor, who will explain what it means and what happens next.
P2 · Physician
“Does this test enable me to triage and make an actionable clinical decision to support and advise my patient?”
Yes. The AIR-DS Lung Test gives you a clear risk result to help you decide who needs further investigation for lung cancer. It supports your clinical judgment. It doesn’t replace it. The AIR-DS Lung Test has shown strong results in a UK clinical study. Healthcare professionals can request the performance data from us.
P3 · Provider / Hospital System
“Can we deliver this at volume, while processing the test locally, without breaking something else?”
Yes. The AIR-DS Lung Test was built for volume, scale and local processing. The swab needs no special handling. Your lab runs the sample on a compatible infrared instrument and then drags and drops the data from the spectrometer into the AIR-DS Lung Test software. From there, the software does the analysis securely in the cloud, in a matter of moments. There’s no specialist lab technician, no software to install, no servers to maintain and no extra interpretation work needed by your team. The AIR-DS Lung Test is designed to detect lung cancer and steer patients into additional clinical precision evaluation, taking pressure off imaging resources and costs rather than adding to them.
P4 · Payer
“How does meaningful value transfer occur when used by a targeted population?”
The AIR-DS Lung Test addresses two of the biggest challenges in lung cancer screening: accessibility and participation. Only 18.7% of eligible individuals currently undergo screening in the U.S. By making testing simple and accessible, the AIR-DS Lung Test aims to increase screening uptake, support earlier detection, improve patient outcomes and experience, support better care team coordination and experience, and reduce the costs associated with treating late-stage disease.
Source: Bandi, P., et al. (2025). Lung cancer deaths prevented and life-years gained from lung cancer screening. JAMA, 334(24), 2225–2227.
P5 · Policy Maker
“How does this change the system, and does it change for the better?”
We think so. A quick, painless test could reach people the current system doesn’t, unlocking value by improving health outcomes for everyone and saving vital imaging resources and the overall cost of treatment within the system. We’re building the evidence to show how it can be implemented to reach more people, and we’ll publish what we find.
P6 · Planet
“What is the impact on the environment, and is the practice sustainable?”
We think so. Because the AIR-DS Lung Test is software, there’s no new machine to build, ship or throw away. Specimen collection and handling don’t require refrigeration or temperature-controlled containers. Tests can be processed locally, eliminating transit and shipping emissions, and use standard infrared instruments that are routinely found in labs. Running the test requires little energy, roughly the same amount required to power a light bulb, and no chemical reagents. There is no blood to discard, and waste is minimized to a simple swab and packaging materials.
Advancing infrared applications for earlier detection — beginning with lung cancer.
AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.